This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Gradishar WJ , Anderson BO , Balassanian R , Blair SL , Burstein HJ , Cyr A , Elias AD , Farrar WB , Forero A , Giordano SH , Goetz MP , Goldstein LJ , Isakoff SJ , Lyons J , Kelly Marcom P , Mayer IA , McCormick B , Moran MS , O'Regan RM , Patel SA , Pierce LJ , Reed EC , Salerno KE , Schwartzberg LS , Sitapati A , Smith KL , Smith ML , Soliman H , Somlo G , Telli M , Ward JH , Shead DA , Kumar R
NCCN Guidelines Insights: Breast Cancer, Version 1.2017
J Natl Compr Canc Netw. 2017 Apr 1;15(4) :433-451
PMID: 28404755 URL: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85017528550&partnerID=40&md5=83eedc6955dca121976f3c3411a3fa7b
AbstractThese NCCN Guidelines Insights highlight the important updates/changes to the surgical axillary staging, radiation therapy, and systemic therapy recommendations for hormone receptor-positive disease in the 1.2017 version of the NCCN Guidelines for Breast Cancer. This report summarizes these updates and discusses the rationale behind them. Updates on new drug approvals, not available at press time, can be found in the most recent version of these guidelines at NCCN.org.
NotesExport Date: 1 May 2017